People · Operator

Matthew Peris

Named in public records as an officer, director or promoter · active 2017–2018 · Biotechnology

1
Companies
5
Filings
$14.6M
Combined raised · real
Single
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
StemoniX, Inc.BiotechnologySeries A$14.6M$3.6M2017
Operator network

Matthew Peris at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

Yung-Ping Yeh · 4 companies · 1 sharedYung-Ping YehMarcus Boehm · 3 companies · 1 sharedMarcus BoehmAndrew LaFrence · 2 companies · 1 sharedAndrew LaFrenceMurdoc Khaleghi · 2 companies · 1 sharedMurdoc KhaleghiPaul Hansen · 2 companies · 1 sharedPaul HansenRobert Petcavich · 2 companies · 1 sharedRobert PetcavichRyan Gordon · 2 companies · 1 sharedRyan GordonSteven Snyder · 2 companies · 1 sharedSteven SnyderBlake Anson · 1 companies · 1 sharedBlake AnsonDavid Buche · 1 companies · 1 sharedDavid BucheDimas Jimenez · 1 companies · 1 sharedDimas JimenezFabian Zanella · 1 companies · 1 sharedFabian ZanellaKevin Gunderson · 1 companies · 1 sharedKevin GundersonPatrick O'Shaughnessy · 1 companies · 1 sharedPatrick O'Shaughn…Sriram Nadathur · 1 companies · 1 sharedSriram NadathurStemoniX, Inc. · $14.6M raisedStemoniX, Inc.Matthew PerisMP
Matthew Peris Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Matthew Peris on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Yung-Ping Yeh14
Marcus Boehm13
Robert Petcavich12
Paul Hansen12
Murdoc Khaleghi12
Ryan Gordon12
Steven Snyder12
Andrew LaFrence12
Sriram Nadathur11
Patrick O'Shaughnessy11
Dimas Jimenez11
Blake Anson11
David Buche11
Fabian Zanella11
Kevin Gunderson11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.